Scopus Author Profile

ผศ.ดร.ภญ.นนทญา นาคคำ

Assist. Prof. Nontaya Nakkam

Research Interest :

• Pharmacogenomics
• Precision Medicine
• Severe Cutaneous Adverse Reactions
• Adverse Drug reactions
• Clinical Pharmacology

Email : nontna@kku.ac.th

Publication (Last 5 years : 2021-2025)

    International Publication

• Mukherjee EM, Gibson A, Krantz MS, Gangula R, Palubinsky AM, Boyd AS, Zwerner JP, Dewan AK, Nakkam N, Konvinse KC, Li Y, Ram R, Chopra A, Phillips EJ. Single-cell immunopathology of recurrent acute generalized exanthematous pustulosis associated with vancomycin. Journal of Allergy and Clinical Immunology: Global. 2025;100426. doi: https://doi.org/10.1016/j.jacig.2025.100426.
  
• Towiwat P, Lawanaskol S, Tassaneeyakul W, Sukasem C, Saksit N, Nakkam N, Poolpun D, Rerkpattanapipat T, Klaewsongkram J, Rerknimitr P, Louthrenoo W. Development of Non-Genetic Risk Stratification Model of Severe Allopurinol Hypersensitivity (NoG-ALLOH Score): A Multicenter Study in Thailand. Journal of Clinical Rheumatology and Immunology. 2024 Nov; 24(supp01):151-152.
  
• Attapong J, Kaset C, Nakkam N, Tassaneeyakul W, Wichukchinda N, Chomean S. Dual approaches in pharmacogenetics: Developing PCR-SSP and RT-PCR methods for HLA-B*13:01 screening to prevent dapsone and Co-trimoxazole SCARs. Heliyon. 2024 August 15;1(15):e34977.
  
• Kategeaw W, Nakkam N, Kiertiburanakul S, Sukasem C, Tassaneeyakul W, Chaiyakunapruk N. Cost-effectiveness analysis of HLA-B*13:01 screening for the prevention of co-trimoxazole-induced severe cutaneous adverse reactions among HIV-infected patients in Thailand. J Med Econ. 2023 Oct 13:1-17. doi: 10.1080/13696998.2023.2270868. Online ahead of print.
  
• Wattanachai P, Amornpinyo W, Konyoung P, Purimart D, Khunarkornsiri U, Pattanacheewapull O, Tassaneeyakul W, Nakkam N. Association between HLA alleles and beta-lactam antibiotics-related severe cutaneous adverse reactions. Front Pharmacol. 2023 Sep 19;14:1248386. doi: 10.3389/fphar.2023.1248386. eCollection 2023.
  
• Nakkam N, Saksit N, Konyoung P, Amornpinyo W, Khunarkornsiri U, Purimart D, Pattanacheewapull O, Naewla T, Wattanachai P, Khaeso K, Chumworathayi P, Tassaneeyakul W. Associations of HLA and drug-metabolizing enzyme genes in co-trimoxazole-induced severe cutaneous adverse reactions. Drug Metab Pharmacokinet. 2022 Oct 18;47:100480. doi: 10.1016/j.dmpk.2022.100480. Epub ahead of print. PMID: 36379177.
  
• Chomean S, Nakkam N, Tassaneeyakul W, Attapong J, Kaset C. Development of label-free electrochemical impedance spectroscopy for the detection of HLA-B*15:02 and HLA-B*15:21 for the prevention of carbamazepine-induced Stevens-Johnson syndrome. Anal Biochem. 2022 Oct 1;658:114931. doi: 10.1016/j.ab.2022.114931. Epub ahead of print. PMID: 36191668.
  
• Khaeso K, Komvilaisak P, Chainansamit SO, Nakkam N, Suwannaying K, Kuwatjanakul P, Hikino K, Dornsena A, Kanjanawart S, Laoaroon N, Vannaprasaht S, Taketani T, Tassaneeyakul W. NUDT15 is a key genetic factor for prediction of hematotoxicity in pediatric patients who received a standard low dosage regimen of 6-mercaptopurine. Drug Metabolism and Pharmacokinetics. 2022 Apr;43: 100436.
  
• Nakkam N, Konyoung P, Amornpinyo W, Saksit N, Tiamkao S, Khunarkornsiri U, Khaeso K, Pattanacheewapull O, Jorns TP, Chumworathayi P, Tassaneeyakul W. Genetic variants associated with severe cutaneous adverse reactions induced by carbamazepine. Br J Clin Pharmacol. 2022 Feb;88(2):773-786. doi: 10.1111/bcp.15022. Epub 2021 Aug 28. PMID: 34350628.
  
• Khaeso K, Udayachalerm S, Komvilaisak P, Chainansamit SO, Suwannaying K, Laoaroon N, Kuwatjanakul P, Nakkam N, Sukasem C, Puangpetch A, Tassaneeyakul W, Chaiyakunapruk N. Meta-Analysis of NUDT15 Genetic Polymorphism on Thiopurine-Induced Myelosuppression in Asian Populations. Front Pharmacol. 2021 Dec 2; 12: 784712.
  
• Nakkam N, Trubiano J, Gibson A, Phillips EJ. Considerations for cross-reactivity between vancomycin and other glycopeptides. J Allergy Clin Immunol Pract. 2021 Aug;9(8):3233. doi: 10.1016/j.jaip.2021.04.013. PMID: 34366100.
  
• Satapornpong P, Pratoomwun J, Rerknimitr P, Klaewsongkram J, Nakkam N, Rungrotmongkol T, Konyoung P, Saksit N, Mahakkanukrauh A, Amornpinyo W, Khunarkornsiri U, Tempark T, Wantavornprasert K, Jinda P, Koomdee N, Jantararoungtong T, Rerkpattanapipat T, Wang CW, Naisbitt D, Tassaneeyakul W, Ariyachaipanich M, Roonghiranwat T, Pirmohamed M, Chung WH, Sukasem C. HLA-B*13:01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients. Front Immunol. 2021 May 4;12:661135.
  
• Pratoomwun J, Thomson P, Jaruthamsophon K, Tiyasirichokchai R, Jinda P, Rerkpattanapipat T, Tassaneeyakul W, Nakkam N, Rerknimitr P, Klaewsongkram J, Srinoulprasert Y, Pirmohamed M, Naisbitt DJ, Sukasem C. Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01. Front Immunol. 2021 Apr 29;12:658593.
  
• Khaeso K, Nakkam N, Komwilaisak P, Wongmast P, Chainansamit SO, Dornsena A, Kanjanawart S, Vannaprasaht S, Tassaneeyakul W. Genetic Polymorphisms of Drug-Metabolizing Enzymes Involved in 6-Mercaptopurine-Induced Myelosuppression in Thai Pediatric Acute Lymphoblastic Leukemia Patients. J Pediatr Genet. 2021 Mar;10(1):29-34.
  
• Nakkam N, Gibson A, Mouhtouris E, Konvinse KC, Holmes NE, Chua KY, Deshpande P, Li D, Ostrov DA, Trubiano J, Phillips EJ. Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A∗32:01–positive vancomycin-induced DRESS sharing an HLA class II haplotype. Journal of Allergy and Clinical Immunology. 2021 Jan;147(1):403-405.